Updated on 24 April 2013
Dr Rao further said that, "We realize that one of the challenges in the vaccine space is clinical trials of new vaccines. DBT is closely working with the DCGI to solve this issue regarding clinical trials."
This has prompted all the major vaccine manufacturers in India to form a Developing Vaccine Manufacturers Network. This industry body is currently in the process of assimilating the necessary demands of the vaccine industry as a collective and not an individual company and then present it to various agencies such as the DBT, Ministry of Health and Family Welfare, and the Indian Council of Medical Research among others.
However, a lot remains to be done. Mr Ranga Iyer, advisor, India Health Progress, said that despite the amazing progress by Indian individuals, "Two million vaccine preventable deaths still occur in India. India has huge capacities for vaccine production, with over 70 percent vaccines manufactured in India being exported. The per capita spend for vaccines for the Indian population is estimated to be only $0.01. When pentavalent vaccines were included in the Universal Immunization Programme
(UIP) last year, the original plan was to expand it to other states. However, until today it remains restricted to the two states of Kerala and Tamil Nadu."
With a substantial vaccine pipeline in store, the next five years could put Indian manufacturers on the innovation map. For now, it appears that the Indian population will have to wait in order to reap the benefits of the vaccine sector's efforts.